Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Super-Bio: Biological Evaluation of SuperMApo
NCT02839278Completed
- Sponsor
- CHU de Besançon
- Start
- Apr 2015
- Primary completion
- Sep 2024
- Modality
- Biologic
- Countries
- 1
01
Overview
Open-label, single-arm trial of SuperMApo in non-ST segment elevation myocardial infarction (NSTEMI), rheumatoid arthritis (RA), chronic obstructive pulmonary disease (COPD) and 7 more, sponsored by CHU de Besançon. Primary endpoint: Expression of costimulatory molecules CD86, CD80, CD40 and class II (HLA-DR) on monocytes at 24 months. Started Apr 2015; status: completed.
02
Drugs
SuperMApo
03
Conditions
non-ST segment elevation myocardial infarction (NSTEMI)rheumatoid arthritis (RA)chronic obstructive pulmonary disease (COPD)idiopathic pulmonary fibrosis (IPF)Crohn's disease
Beyond the preview
Go deeper on NCT02839278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02839278.